Disease · MONDO_0005382
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Zoledronic Acid vs Risedronate: serious adverse events | 4 of 88 | 3 of 90 | 178 | NCT00103740 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Had Therapeutic Response at 6 Months | 84 of 88 | 67 of 89 | 177 | NCT00103740 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 | 8 of 88 | 1 of 88 | 176 | NCT00103740 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: serious adverse events | 5 of 89 | 8 of 82 | 171 | NCT00051636 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Achieve Therapeutic Response at 6 Months. | 85 of 88 | 60 of 82 | 170 | NCT00051636 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 Relative to Baseline | 5 of 88 | 0 of 82 | 170 | NCT00051636 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period | 10 of 78 | 42 of 63 | 141 | NCT00103740 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Partial Disease Relapse During the Extended Observation Period | 9 of 78 | 37 of 63 | 141 | NCT00103740 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Disease Relapse During the Extended Observation Period | 0 of 78 | 15 of 63 | 141 | NCT00103740 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period | 8 of 75 | 29 of 52 | 127 | NCT00051636 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Partial Disease Relapse During the Extended Observation Period | 6 of 75 | 26 of 52 | 127 | NCT00051636 | Trial comparisons |
| Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Disease Relapse During the Extended Observation Period | 0 of 75 | 7 of 52 | 127 | NCT00051636 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005382/comparisons